Spherix News

BETHESDA, Md., April 18, 2012 /PRNewswire/ -- Spherix Incorporated - an innovator in biotechnology for therapy in diabetes, metabolic syndrome and atherosclerosis, and provider of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies - today announced results from its recently completed studies ... (more)

In addition to its own combination drugs, Spherix is looking at Phase 1 and Phase 2 assets to roll-up in this platform.

Spherix Inc., of Bethesda, a biopharmaceutical developer and provider of regulatory consulting services, reported it cut its net loss in 2011 to $3.5 million, or $1.32 per diluted share, from a net loss of $7.7 million, or $4.28 per diluted share, in 2010.

Spherix to Present Newest Work on Lipoproteins and Atheromas at Pittcon, the World's Largest Annual Expo for Laboratory Science /PRNewswire/ --A Spherix Incorporated - an innovator in biotechnology for therapy in diabetes, metabolic syndrome and atherosclerosis, and providers of technical and regulatory consulting services to food, supplement, ... (more)

Atherosclerosis can lead to myocardial infarction and stroke. Each year, about 770,000 people in Two groups of apolipoprotein E-deficient mice were each fed a Western diet for eight weeks.